Literature DB >> 19303901

Glycosphingolipids and insulin resistance.

Mirjam Langeveld1, Johannes M F G Aerts.   

Abstract

Obesity is associated with an increased risk for insulin resistance, a state characterized by impaired responsiveness of liver, muscle and adipose tissue to insulin. One class of lipids involved in the development of insulin resistance are the (glyco)sphingolipids. Ceramide, the most simple sphingolipid, directly inhibits phosphorylation of the insulin signaling mediator Akt/Protein Kinase B. More complex glycosphingolipids, so-called gangliosides, block phosphorylation of the insulin receptor and down-stream signaling, possibly by exclusion of the insulin receptor from specific membrane domains. Pharmacological inhibition of glycosphingolipid synthesis is found to markedly improve insulin sensitivity in rodent models of insulin resistance. Partial glycosphingolipid reduction is well tolerated and may thus offer an attractive new treatment modality for obesity-induced insulin resistance and type II diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303901     DOI: 10.1016/j.plipres.2009.03.002

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  48 in total

1.  Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Edward Re; Lisa Longato; Ming Tong
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

3.  Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells.

Authors:  Marimuthu Subathra; Midhun Korrapati; Lauren A Howell; John M Arthur; James A Shayman; Rick G Schnellmann; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

4.  Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin.

Authors:  Ming Tong; Lisa Longato; Teresa Ramirez; Valerie Zabala; Jack R Wands; Suzanne M de la Monte
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

Review 5.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 6.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

7.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

Review 8.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

9.  Stimulation of GLUT4 (glucose transporter isoform 4) storage vesicle formation by sphingolipid depletion.

Authors:  Zhi-Jie Cheng; Raman Deep Singh; Teng-Ke Wang; Eileen L Holicky; Christine L Wheatley; David A Bernlohr; David L Marks; Richard E Pagano
Journal:  Biochem J       Date:  2010-03-15       Impact factor: 3.857

10.  Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase.

Authors:  Nelson S Yew; Hongmei Zhao; Eun-Gyoung Hong; I-Huan Wu; Malgorzata Przybylska; Craig Siegel; James A Shayman; Cynthia M Arbeeny; Jason K Kim; Canwen Jiang; Seng H Cheng
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.